BEYOND AIR INC

XAIRNASDAQ

🏆 #3894 by market capEarnings Aug 13US Equity

$5.84▲ $0.72 (+12.31%)

Live

1h—

24h▲ 12.3%

7d—

14d—

30d—

1y—

🏦Market Cap

$4M

Small Cap

📈Revenue Growth (YoY)

+107.3%

High Growth

📊Gross Margin

3.3%

Thin

💵FCF Margin

—

⚖️P/S Ratio

0.6x

Cheap

Otter Score

Weak

No chart data available for XAIR.

Trading Snapshot

Day Range: $5.76 – $5.93
52-Week Range: $5.02 – $95.60
Volume: $2.42B
Avg Volume: $3.15B
Shares Outstanding: 720,000
Next Earnings: Sep 24, 2026

Fundamentals Snapshot

Annual Revenue: $8M
Last Q Revenue: $2M
P/E Ratio: —
P/S Ratio: 0.6x
EPS (TTM): $-59.12
Dividend Yield: —

Why Investors Own XAIR

✓High-growth profile — revenue up +53.6% YoY with expanding US Equity exposure.
✓Healthy economics — 40% gross margin and 23% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$8M▲ +46.4% YoY

Gross Margin (TTM)

40.0%▲ +3.7% YoY

Operating Income (TTM)

$2M▲ +46.4% YoY

Free Cash Flow (TTM)

$2M▲ +46.4% YoY

About BEYOND AIR INC

Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.

🦦